IMU Target $2.00 - Not Ramping !!!, page-2

I’ll have a crack, back of an envelope calcs … with a view 5 years into the future.
Pretty sure both the Vaxinia and CheckVaxx phase 1 trials are scheduled to be completed next year. Data will be peer reviewed etc.
If the data is compelling, which some of us re hopeful it is, they can apply for FDA fast track.
Nick Ede has said they are targeting the $400B unmet solid tumour market.
So, say they have something to market in 2025 and …
In 2025 they account for 5% of the $400B solid tumour market so $20B in sales.
2026 they are at 15%, so $60B in sales.
2027 they are at 35%, so $140B in sales.
$220B in sales / 6.42B SOI = $34.28/share.
Less costs, PH parties etc, let’s say 50% reduction, so $17.33/share.
Haven’t done any conversions from USD to AUD because I can’t remember if the $400B was in US or AUD.
Soz … based on the above I can’t get near the $2/share that valueadd got, looks like that could be a conservative number.
Happy to be corrected, and state the above is hypothetical.